Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1337-1343

  Mohammad, Ramzi M ^a   Varterasian, Mary L ^a   Almatchy, Victor P ^a   Hannoudi, Ghadeer N ^a   Pettit, George R ^b   Al Katib, Ayad ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AURISTATIN PE; BRYOSTATIN 1; DOLASTATIN 10; NATURAL PRODUCT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG ISOLATION; DRUG POTENTIATION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOLLUSC; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL COUNT; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LACTONES; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MACROLIDES; MICE; MICE, SCID; MITOSIS; OLIGOPEPTIDES; SUBRENAL CAPSULE ASSAY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0031948608     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Foon, K. A., Rai, K. R., and Gale, R. P. Chronic lymphocytic leukemia: new insights into biology and therapy. Ann. Intern. Med., 113: 525-539, 1990.
2. Keating, M. J. Chemotherapy of chronic lymphocytic leukemia. In: B. D. Cheson (ed.), Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments, pp. 297-336. New York: Marcel Dekker, Inc., 1993.
3. Pettit, G. R., Herald, C. L., Doubek, D. L., Herald, D. L., Arnold, E., and Clardy, J. Isolation and structure of Bryostatin 1. J. Am. Chem. Soc., 104: 6846-6848, 1982.
4. Pettit, G. R. The bryostatins. In: W. Herz, G. W. Kirby, W. Steglich, and C. H. Tamm (eds.), Progress in the Chemistry of Organic Natural Products, pp. 154-195. New York: Springer-Verlag, 1991.
5. Hornung, R. L., Pearson, J. W., Beckwith, M., and Longo, D. L. Preclinical evaluation of bryostatin 1 as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res., 52: 101-107, 1992.
6. Stone, R. M., Sariban, E., Pettit, G. R., and Kufe, D. W. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood, 72: 208-213, 1988.
7. Al-Katib, A., Mohammad, R. M., Dan, M., Hussein, M. E., Akhtar, A., Pettit, G. R., and Sensenbrenner, L. L. Bryostatin 1 induced hairy cell features on chronic lymphocytic leukemia cells in vitro. Exp. Hematol. (Charlottesville), 21: 61-65, 1993.
8. Mohammad, R. M., Al-Katib, A., Pettit, G. R., and Sensenbrenner, L. L. Differential effects of bryostatin 1 on human non-Hodgkin's B-lymphoma cell lines. Leuk. Res., 17: 1-8, 1993.
9. Mohammad, R. M., Al-Katib, A., Pettit, G. R., and Sensenbrenner, L. L. Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res., 54: 165-168, 1994.
10. Pettit, G. R., Kamano, Y., Herald, C. L., Tuinman, A. A., Boettner, F. E., Kizu, H., Schmidt, J. M., Baczynskyj, L., Tomer, K. B., and Bontems, R. J. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J. Am. Chem. Soc., 109: 6883-6894, 1987.
11. Pettit, G. R. The dolastatins. In: W. Herz, G. W. Kirby, R. E. Moore, W. Steglich, and C. H. Tamm (eds.), Progress in the Chemistry of Organic Natural Products, pp. 2-63. New York: Springer-Verlag, 1997.
12. Bai, R., Roach, M. C., Jayaram, S. K., Barkoczy, J., Pettit, G. R., Luduena, R. F., and Hamel, E. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin: correlation with cytotoxicity. Biochem. Pharmacol., 45: 1503-1515, 1993.
13. Pettit, G. R., Srirangam, J. K., Barkoczy, J., Williams, M. D., Durkin, K. P., Boyd, M. R., Bai, R., Hamel, E., Schmidt, J. M., and Chapuis, J. C. Antineoplastic agents 337: synthesis of dolastatin 10 structural modifications. Anticancer Drug Design, 10: 529-544, 1995.
14. Mohammad, R. M., Mohamed, A. N., Hamdan, M. Y., Vo, T., Chen, B., Katato, K., Abubakr, Y. A., Dugan, M. C., and Al-Katib, A. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia (Baltimore), 10: 130-137, 1996.
15. Maki, A., Diwakaran, H., Redman, B., Al-Asfar, S., Pettit, G. R., Mohammad, R. M., and Al-Katib, A. The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs, 6: 392-297, 1995.
16. Mohammad, R. M., Diwakaran, H., Maki, A., Emara, M. A., Pettit, G. R., Redman, B., and Al-Katib, A. Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk. Res., 19: 667-673, 1995.
17. Corbett, T. H., Valeriote, F. A., Polin, L., Panchapor, C., Pugh, S., White, K., Lowinchik, N., Knight, J., Bissery, M. C., Wozniak, A., LoRusso, P., Biernat, L., Polin, D., Knight, L., Biggar, S., Looney, D., Demchik, L., Jones, J., Jones, L., Blair, S., Palmer, K., Essenmacher, S., Lisow, L., Mattes, K. C., Cavanaught, P. F., Rake, J. B., and Baker, L. Discovery of solid tumor active agents using a soft-agar-colony-formation disk-diffusion assay. In: F. A. Valeriote, T. H. Corbett, and L. H. Baker (eds.), Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, pp. 35-87. Boston: Kluwer Academic Publishers, 1992.
18. Dancescu, M., Rubio-Trujillo, M., Biron, G., Bron, D., Delespesse, G., and Sarfati, M. Interleukin 4 protects chronic lymphocytic leukemia B cells from death by apoptosis and up-regulates Bcl-2 expression. J. Exp. Med., 176: 1319-1326, 1992.
19. Hoffbrand, A. V., Panayiotidis, P., Reittie, J., and Ganeshaguru, K. Autocrine and paracrine growth loops in chronic lymphocytic leukemia. Semin. Hematol., 30: 306-317, 1993.
20. Cheson, B., Bennet, J., Rai, K., Grever, M., Kay, N., Schiffer, C., Oken, M., Keating, M., Boldt, B., Kempin, S., and Foon, K. Guidelines for the classification of chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am. J. Hematol., 29: 152-163, 1988.
21. Robertson, L. E., Chubb, S., Meyn, R. E., Story, M., Ford, R., Hittelman, W. N., and Plunkett, W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood, 81: 143-150, 1993.
22. Bai, R., Pettit, G. R., and Hamel, E. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal: inhibition of tubulin polymerization mediated through the Vinca alkaloid binding domain. Biochem. Pharmacol., 39: 1941-1949, 1990.
23. Luduena, R. F., Roach, M. C., Prasad, V., and Pettit, G. R. Interaction of dolastatin 10 with bovine brain tubulin. Biochem. Pharmacol., 43: 539-543, 1992.
24. Grant, S., and Jarvis, D. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin. Cancer Res., 2: 1915-1920, 1996.